they did a job on us, small correction

Why Peptech shareholders are so unhappy

REALLY IMPORTANT INFORMATION FOR ALL HOLDERS

As Board members of Evogenix BEAUMONT, HARRIS AND JESSUP sold Evogenix to Peptech

They merged with Peptech valuing Evogenix at $156 million dollars

That valued Evogenix at $1.12 a share,

Now with over 200 million in cash and receivables adding the cost paid for Evogenix equates to $356 Million

NOW BEAUMONTand HARRIS sell the entire entity (Peptech and Evogenix now Arana) for 318 Million TO Cephalon.

TAKE OFF the Evogenix $1.12 from the Cephalon offer of $1.40 and you have a value of 0.28c for every Peptech share.

0.28c compared to around $2.00 that we were trading at prior to the merger with Evogenix.

THEY DID THE JOB ON US

BEAUMONT, HARRIS AND JESSUP obtained

NO VALUE for any of the pipeline including ART621, PNO615, ART123, ART010, ART104, ART150

NO VALUE for the platforms, Evogene, Synhumanisation, the domantis dAb targets remaining and Superhumanisation

NO VALUE for the licensing agreements with JNJ and Centocor.

NO VALUE for Co-Development agreements with Greenovation, Kyowa, Aveo, Vengenics, CSL.

This essentially values Peptech now as 0.28c a share when before the merger Peptech was close to $2.00 a share.

We have well and truly been done over.

ASIC now has over 20 complaints.

If what I have just written does not get your blood boiling, your dead.

Get the complaints to ASIC as soon as possible, DOWN LOAD FROM THE ASIC WEBSITE

ALSO PLEASE NOTE, THERE WAS NEVER EVER ANY INTENTION BY CEPHALON TO DO A HOSTILE TAKEOVER.

IHMO IT DOES LOOK LIKE THE BOARD GOT VERY LAZY AND OFFERED THE WHOLE COMPANY INSTEAD OF WHAT CEPHALON REALLY WANTED ART621.